Dr. Sharon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6140Fax+1 617-632-2933
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2007 - 2011
Emory University School of MedicineResidency, Internal Medicine, 2003 - 2006
Baylor College of MedicineClass of 2003
Certifications & Licensure
MA State Medical License 2008 - 2026
DC State Medical License 2012 - 2024
GA State Medical License 2006 - 2017
MD State Medical License 2012 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 31 citationsMajor Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.Abdul Rafeh Naqash, Melissa Y Y Moey, Xiao-Wei Cherie Tan, Mehak Laharwal, Vanessa Hill
Journal of Clinical Oncology. 2022-10-10 - 218 citationsNeoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost
The New England Journal of Medicine. 2023-03-02 - 11 citationsCabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.Daniel M Girardi, Scot A Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara
Clinical Cancer Research. 2022-04-01
Journal Articles
- Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyMichael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
- Immuno-Oncology Trial Endpoints: Capturing Clinically Meaningful ActivityElad Sharon, Patrick M Forde, Valsamo Anagnostou, Hao Wang, Franco Verde, Mark Yarchoan, Clinical Cancer Research
- From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials WiselyArta M Monjazeb, Elad Sharon, Clinical Cancer Research
Authored Content
- Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018
Press Mentions
Rare Melanoma Very Likely to Respond to Treatment with PembrolizumabMay 5th, 2023- Slips, Slides: Winter Injuries Can Be SeriousJanuary 2nd, 2023
- Drug Approved to Help Young Patients Battle a Rare CancerJanuary 2nd, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
